Cite
The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance.
MLA
Zou, Jianxuan, et al. “The Novel Protein Homeostatic Modulator BTX306 Is Active in Myeloma and Overcomes Bortezomib and Lenalidomide Resistance.” Journal of Molecular Medicine, vol. 98, no. 8, Aug. 2020, pp. 1161–73. EBSCOhost, https://doi.org/10.1007/s00109-020-01943-6.
APA
Zou, J., Jones, R. J., Wang, H., Kuiatse, I., Shirazi, F., Manasanch, E. E., Lee, H. C., Sullivan, R., Fung, L., Richard, N., Erdman, P., Torres, E., Hecht, D., Lam, I., McElwee, B., Chourasia, A. H., Chan, K. W. H., Mercurio, F., Stirling, D. I., & Orlowski, R. Z. (2020). The novel protein homeostatic modulator BTX306 is active in myeloma and overcomes bortezomib and lenalidomide resistance. Journal of Molecular Medicine, 98(8), 1161–1173. https://doi.org/10.1007/s00109-020-01943-6
Chicago
Zou, Jianxuan, Richard J. Jones, Hua Wang, Isere Kuiatse, Fazal Shirazi, Elisabet E. Manasanch, Hans C. Lee, et al. 2020. “The Novel Protein Homeostatic Modulator BTX306 Is Active in Myeloma and Overcomes Bortezomib and Lenalidomide Resistance.” Journal of Molecular Medicine 98 (8): 1161–73. doi:10.1007/s00109-020-01943-6.